Genzyme Corp. bolstered its oncology portfolio through a potential $2.9 billion deal with partner Bayer AG that gives Genzyme rights to the marketed cancer drugs Campath (alemtuzumab), Fludara (fludarabine) and Leukine (sargramostim) - as well as control of the Phase III alemtuzumab program in multiple sclerosis. (BioWorld Today) Read More
